Cenix BioScience Delivers on Target Discovery Collaboration
The method of identification, based on detailed analysis of RNAi-induced loss-of-function phenotypes in living human cells, conveys upon these targets a significantly stronger patho-physiological relevance than that typically seen for targets identified by less probative "first-wave" genomics methodologies of recent years. As such, the higher level of validation delivered by Cenix inherently offers superior predictive value regarding the future therapeutic potential of drug candidates developed from these targets.
According to the collaboration announced in December 2003, Bayer acquired the first option to secure all rights to new target-related intellectual property generated by the project. As a result, Bayer's decision to seek patent protection on the present targets triggered unspecified milestone payments to Cenix.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.